Rise and shine, everyone, the middle of the week is already here. But time waits for no one, of course. Meanwhile, a hazy, muggy morning is unfolding here on the Pharmalot campus, where the officials mascot is noisily snoozing in a corner and the short people are preoccupied, as they should be. As for us, we are downing yet another needed cup of stimulation. Feel free to join us, as always. And here are some tidbits to help you along. Have a wonderful day and keep in touch. …

A trio of key White House advisers hinted for the first time that they could support a progressive proposal to cap price increases for certain medicines, speaking at a closed-door Capitol Hill briefing of Republican senators, STAT reports. The administration’s openness to the idea — which has not yet earned formal support of many Democrats, let alone Republicans — serves as the latest evidence that the Trump administration has become increasingly reliant on Capitol Hill for a victory on drug costs and, perhaps, increasingly pliable on policy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy